Professor zur Hausen, who received the Nobel Prize in Physiology or Medicine in 2008 for his discovery of HPV as the cause of cervical cancer, explained that, although HPV prevention will impact mainly on women’s health, it also has important implications for men’s health: ‘If we wish to achieve eradication within a reasonable period of time, we will need to vaccinate both sexes, and research has shown that boys respond to vaccination in the same way as girls. The main risk of developing cancer after HPV infection is with women and, because of the cost of vaccines, it has been decided to start with girls,’ the professor said. ‘But other cancers associated with HPV infection, such as anal and oral cancer, are more common in men, and genital warts occur in both sexes. So there is good reason to vaccinate boys before the onset of sexual activity as well.'
Prof. Hausen suggested that future reductions in production costs and development of cheaper vaccines will make wider vaccination a realistic option, and added that a major reduction in HPV 16 and 18 – the viruses that cause 70-80% of human papilloma infections – would probably enable the interval between currently used cervical screening tests to be extended. The introduction of self sampling by women, using new tests for HPV DNA, would also help to simplify screening procedures.
‘A therapeutic intervention is also needed to protect people after they have acquired HPV infection, and it would be a great advantage to have targeted chemotherapy that would block viral functions that are responsible for development of precursor and malignant lesions.’ he pointed out. ‘A lot of laboratories are working on this and, although I know of nothing yet, it will hopefully not be too long before we see progress.’